<DOC>
	<DOCNO>NCT00491140</DOCNO>
	<brief_summary>The primary objective identify molecular feature predict response resistance cetuximab</brief_summary>
	<brief_title>Retrospective Study Assessing Molecular Features Predicting Response Cetuximab</brief_title>
	<detailed_description>Secondary objective investigate association genomic status EGFR HER-2 gene clinical outcome , include objective response , time progression survival</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Histologically confirm diagnosis colorectal cancer available tumor tissue clinical data ; presence least one measurable lesion . Less 3 week completion previous radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>EGFR</keyword>
	<keyword>KRAS</keyword>
	<keyword>BRAF</keyword>
	<keyword>MET</keyword>
	<keyword>IGFR1</keyword>
</DOC>